{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T10:47:51Z","timestamp":1787482071447,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ALF Region \u00d6stergotland","award":["LIO-697991, LIO- 707011, and LIO-697461"],"award-info":[{"award-number":["LIO-697991, LIO- 707011, and LIO-697461"]}]},{"name":"CKOC Region \u00d6sterg\u00f6tland","award":["-"],"award-info":[{"award-number":["-"]}]},{"DOI":"10.13039\/100010805","name":"Medical Research Council of Southeast Sweden","doi-asserted-by":"crossref","award":["FORSS-751541"],"award-info":[{"award-number":["FORSS-751541"]}],"id":[{"id":"10.13039\/100010805","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Futurum, Academy for Health and Care J\u00f6nk\u00f6ping County Council","award":["695491"],"award-info":[{"award-number":["695491"]}]},{"name":"Swedish Cancer Society","award":["-"],"award-info":[{"award-number":["-"]}]},{"name":"Sveriges Gastro-Onkologiska F\u00f6rening","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. Nevertheless, a majority of patients do not respond to treatment. In order to guide the individual patient to the most beneficial therapeutic strategy, simple and easily available prognostic and predictive markers are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The potential prognostic value of a range of blood\/serum parameters, patient-, and tumour characteristics was explored in a retrospective cohort of 75 patients treated with gemcitabine\/nab-paclitaxel (Gem\/NabP) for advanced pancreatic ductal adenocarcinoma (PDAC) in the South Eastern Region of Sweden. Primary outcome was overall survival (OS)\u00a0while progression free survival\u00a0(PFS) was the key secondary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      Univariable Cox regression analysis revealed that high baseline serum albumin (&gt;\u200937\u2009g\/L) and older age (&gt;\u200965) were positive prognostic markers for OS, and in multivariable regression analysis both parameters were confirmed to be independent prognostic variables (HR 0.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023 and HR\u2009=\u20090.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039,). Thrombocytopenia at any time during the treatment was an independent predictor for improved progression free survival (PFS) but not for OS (HR 0.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029, 0.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.073), whereas thrombocytopenia developed under cycle 1 was neither related with OS nor PFS (HR 0.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.384, HR 1.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.771). Other parameters assessed (gender, tumour stage, ECOG performance status, myelosuppression, baseline serum CA19\u20139, and baseline serum bilirubin levels) were not significantly associated with survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum albumin at baseline is a prognostic factor with palliative Gem\/NabP in advanced PDAC, and should be further assessed as a tool for risk stratification. Older age was associated with improved survival, which encourages further studies on the use of Gem\/NabP in the elderly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07426-8","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T06:02:58Z","timestamp":1601618578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical characteristics and blood\/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel"],"prefix":"10.1186","volume":"20","author":[{"given":"Hakon","family":"Blomstrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Fredrikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gr\u00e4nsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergthor","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils O.","family":"Elander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"issue":"4","key":"7426_CR1","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/annonc\/mdy033","volume":"29","author":"M Malvezzi","year":"2018","unstructured":"Malvezzi M, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018;29(4):1016\u201322.","journal-title":"Ann Oncol"},{"issue":"6","key":"7426_CR2","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403\u201313.","journal-title":"J Clin Oncol"},{"issue":"19","key":"7426_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"7426_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"2","key":"7426_CR5","doi-asserted-by":"publisher","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","volume":"107","author":"D Goldstein","year":"2015","unstructured":"Goldstein D, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2):dju413.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"7426_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"7426_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12885-018-5244-2","volume":"19","author":"H Blomstrand","year":"2019","unstructured":"Blomstrand H, et al. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019;19(1):40.","journal-title":"BMC Cancer"},{"issue":"3","key":"7426_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00280-019-03895-2","volume":"84","author":"U Ishimoto","year":"2019","unstructured":"Ishimoto U, et al. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Cancer Chemother Pharmacol. 2019;84(3):647\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"7426_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1186\/s12885-018-4665-2","volume":"18","author":"J Betge","year":"2018","unstructured":"Betge J, et al. A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +\/\u2212 nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer. 2018;18(1):747.","journal-title":"BMC Cancer"},{"issue":"3","key":"7426_CR10","first-page":"270","volume":"11","author":"Y Nakano","year":"2019","unstructured":"Nakano Y, et al. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Mol Clin Oncol. 2019;11(3):270\u20138.","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"7426_CR11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/bjs.11111","volume":"106","author":"M Strijker","year":"2019","unstructured":"Strijker M, et al. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. Br J Surg. 2019;106(4):342\u201354.","journal-title":"Br J Surg"},{"issue":"9","key":"7426_CR12","first-page":"106","volume":"28","author":"H Yoneyama","year":"2017","unstructured":"Yoneyama H, et al. Risk factors for neutropenia during gemcitabine and nanoparticle albumin bound paclitaxel combination chemotherapy. Abstract P3\u2013089, Ann Oncol. 2017;28(9):106.","journal-title":"Abstract P3\u2013089, Ann Oncol"},{"issue":"2","key":"7426_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1634\/theoncologist.2014-0394","volume":"20","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20(2):143\u201350.","journal-title":"Oncologist"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07426-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T19:43:10Z","timestamp":1633117390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07426-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7426"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07426-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18714\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18714\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18714\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18714\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Ethics Review Board in Link\u00f6ping (diary number 2017\/110\u201331). An exemption from informed consent from participating patients was granted based on the retrospective and non-interventional nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"950"}}